Fig. 2From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabProgression free survival in patients treated in the first line (A) and in the second or further line (B). Overall survival in patients treated in the first line (C) and in the second or further line (D)Back to article page